About Us
About Us
We are a preclinical biotechnology company developing drugs designed to transform radiation therapy by preventing short and long-term side effects of radiation therapy. Our novel mechanism-based nanoparticle is designed to prevent normal tissue damage from radiation therapy without interfering with the effectiveness of radiation on the cancerous tissue. We have developed two formulations of cerium oxide nanoparticle particle drug product. This includes an IV formulation for the protection of normal internal tissue and a topical formulation for the protection of skin from radiation damage. The drug products have been studied in proof-of-concept animal models of breast, lung, head and neck, pancreatic, prostate, and colorectal cancers. Our IV and topical formulation positive preclinical data in these animal models indicate the potential use in multiple cancers. Our clinical development program is designed to mitigate the harmful side effects associated with radiation therapy. Fast track and orphan drug designations by the FDA for our drugs under development is possible. We have established an experienced Medical and Scientific Advisory Board, with some of the preeminent leaders in the fields of medical oncology and radiation therapy. Our management team has over 150 years of combined experience in international markets, drug development and investment banking.
